Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.to-BBB, a Dutch drug brain delivery company, is executing a pilot study with Janssen Pharmaceutica, an international pharmaceutical company under the Johnson & Johnson group, to enhance delivery of drugs to the brain for central nervous system (CNS) diseases.
Subscribe to our email newsletter
The pilot study with to-BBB is expected to allow researchers of Janssen to investigate the capabilities of the G-Technology to enhance delivery of their investigational compounds to the CNS.
to-BBB said that its proprietary G-Technology is a safe technology for drug delivery to the brain. It is based on liposomes that are coated with the tripeptide glutathione at the tips of polyethylene glycol (PEG) to safely enhance the delivery of free drug to the brain. Proof of concept with the G-Technology is demonstrated in several disease models, including pain, brain tumors and viral encephalitis.
Pieter Gaillard, CSO, said: “We are very proud to join forces with Janssen. to-BBB’s brain delivery technology combined with Janssen’s rich history in neuroscience discovery and broad range of potential compounds for brain diseases, will hopefully lead to new therapeutic options for patients.”